Pantarhei Bioscience (PRB) specialises in the clinical development of patent protected innovative medical uses of existing hormones and steroidal drugs in Women’s Health (WH), whereas the spin-off company Pantarhei Oncology (PRO) is focusing on reproductive tract related cancer including breast and prostate cancer. Both Pantarhei companies develop new treatment concepts until and including proof-of-concept in the human (phase 2). Thereafter the products are licensed out for final phase 3 development and sales and marketing to big pharma companies.
Prioritised projects are E4, ARC and ZP3. E4 is the fetal estrogen estetrol, suitable for WH applications such as contraception, HRT and add-back in endometriosis and for oncological applications such as breast and prostate cancer. E4 has been licensed out to Mithra Pharmaceuticals in Liège, Belgium. Mithra will develop the WH applications of E4, whereas PRO has retained the rights to develop the oncological applications. ARC is the acronym for Androgen Restored Contraception, referring to normalisation of free testosterone levels during the use of combined oral contraceptives by adding DHEA to the pill and thereby improving sexual function and mood. ZP3 refers to a new treatment of metastasised ovarian cancer by immunisation against the specific ovarian antigen zona pellucida 3 in a collaboration between PRO and HRA Pharma in Paris, France. PRO is developing immunological treatments for other ZP3 expressing tumors.
Contact Details
Pantarhei Bioscience, Boslaan 11, 3701 CH Zeist, the Netherlands
tel +31 30 6985020,
fax + 31 30 6985021
See our Cookie Privacy Policy Here
